Parta Hatamizadeh

Parta Hatamizadeh practices at UF Dialysis Center in Gainesville, Florida.

Parta Hatamizadeh's NPI, 1861668824, was assigned on April 30, 2008. Parta Hatamizadeh graduated from Tehran University of Medical Sciences School of Medicine in 1998. Parta Hatamizadeh holds Florida license ME130286.

Parta Hatamizadeh's primary practice is UF Dialysis Center, at 3850 Nw 83rd St Ste 101, Gainesville, FL 32606 in Alachua County. The practice phone is (352) 337-6021.

Parta Hatamizadeh's primary practice is UF Dialysis Center in Gainesville, Florida. Parta Hatamizadeh is also affiliated with UF Health Shands Hospital. The medical group on file is UF Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Parta Hatamizadeh practices, 2 sites in all. Vendor and product names are available with a free account.

Nephrology is Parta Hatamizadeh's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Parta Hatamizadeh is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Parta Hatamizadeh's licenses on file in 6 states: Florida, Alabama, Ohio, California, Michigan and Pennsylvania.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances and parathyroid gland disorder among the conditions Parta Hatamizadeh treats.

CMS data shows 823 Medicare services from Parta Hatamizadeh across 8 procedure codes in 2024, for 257 Medicare patients. Medicare paid $70,652 for them.

CMS counts 257 Medicare patients who saw Parta Hatamizadeh in 2024. The largest group is 75 to 84, with 86 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 33% are also on Medicaid. Their average risk score is 4.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Parta Hatamizadeh's median patient age at 74, with 49% women.

In 2024, Parta Hatamizadeh wrote 629 Medicare Part D claims for 111 patients. 99% of them were for generic drugs. CMS names the drug for 561 of them, across 12 drugs with 11 or more claims each, at $9,185 in total drug cost. In 2023, CMS named 435 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 48 out of 100 for Parta Hatamizadeh for performance year 2024, reported through an alternative payment model (APM). Parta Hatamizadeh accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 21 papers to Parta Hatamizadeh, published from 2007 to 2025. 2012 was the busiest year, with 6. The most frequent topics are Heart Failure, Cardiomyopathies and Coronary Circulation. Parta Hatamizadeh has published most often in J Card Fail. Parta Hatamizadeh's most frequent co-authors are Kamyar Zadeh Kalantar-Zadeh, MD, Munir S. Janmohamed, MD and Csaba Pal Kovesdy, MD.

CMS Open Payments shows 27 general payments to Parta Hatamizadeh from 7 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 45% of the total. Amgen Inc. paid the most, $3,410.

Parta Hatamizadeh graduated from Tehran University of Medical Sciences School of Medicine in 1998.

Parta Hatamizadeh is in network with 17 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.